Physician profile
Manjinder Kaur
NPI 1487865309
$57,771.52
in general payments reported to CMS, 2019-2025
33 companies · $40K in 2025
The $40K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $255 · 2021: $104 · 2022: $205 · 2023: $357 · 2024: $17K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $5,206 · Travel and Lodging: $1,926 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,734.69 |
| Food and Beverage | $5,206.24 |
| Travel and Lodging | $1,926.09 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $47,000.21 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $8,850.57 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Beta Bionics, INC. | $244.15 | 2024 | Ilet Bionic Pancreas |
| Corcept Therapeutics | $204.06 | 2020-2025 | Korlym |
| Ascendis Pharma Endocrinology INC | $195.67 | 2025 | Yorvipath |
| Dexcom, INC. | $190.80 | 2019-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $126.87 | 2019-2024 | Freestyle Libre 3 |
| Medtronic, INC. | $103.44 | 2021-2024 | Minimed 780g |
| Amgen INC. | $90.68 | 2024-2025 | Tepezza, Evenity |
| Abbvie INC. | $85.56 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $81.70 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Esperion Therapeutics, INC. | $63.18 | 2020-2025 | Nexletol |
| Xeris Pharmaceuticals, INC. | $62.32 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $59.40 | 2019-2024 | |
| Radius Health, INC. | $53.38 | 2019-2025 | Tymlos |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $41.43 | 2019-2020 | |
| Insulet Corporation | $32.51 | 2022-2023 | Omnipod |
| Vivus LLC | $31.53 | 2019-2021 | |
| Kyowa Kirin, INC. | $23.32 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.28 | 2023 | Jardiance |
| Alexion Pharmaceuticals, INC. | $22.25 | 2019 | |
| Neurocrine Biosciences, INC. | $21.83 | 2024 | |
| Novartis Pharmaceuticals Corporation | $18.46 | 2025 | |
| Dermira, INC. | $17.24 | 2019 | |
| Recordati_rare_diseases_inc. | $16.22 | 2025 | Isturisa |
| Grt US Holding, INC. | $15.63 | 2022 | |
| Amryt Pharma Holdings Ltd | $15.51 | 2023 | Mycapssa |
| Cequr Corporation | $14.71 | 2024 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $14.15 | 2022 | |
| Amarin Pharma, INC. | $14.09 | 2020 | |
| Clarus Therapeutics INC. | $13.70 | 2021 | |
| Ibsa Pharma INC. | $13.56 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manjinder Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.